{
  "meta": {
    "title": "42_Perimenopause_Menopause_And_Post-Menopausal_Bleeding",
    "url": "https://brainandscalpel.vercel.app/42-perimenopause-menopause-and-post-menopausal-bleeding-f128a77d.html",
    "scrapedAt": "2025-11-30T12:30:06.019Z"
  },
  "questions": [
    {
      "text": "Menopause is defined as cessation of menses for a period of _____.",
      "choices": [
        {
          "id": 1,
          "text": "3 months"
        },
        {
          "id": 2,
          "text": "6 months"
        },
        {
          "id": 3,
          "text": "9 months"
        },
        {
          "id": 4,
          "text": "12 months"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p>Menopause is defined as cessation of ovarian function&nbsp;for <strong>12 months</strong> resulting in permanent amenorrhoea. It is a <strong>retrospective diagnosis.</strong></p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC0881",
      "difficulty": "easy"
    },
    {
      "text": "A woman with menorrhagia is diagnosed with uterine fibroids. Prior to starting treatment, you want to check if she is premenopausal. On which day of the menstrual cycle will you estimate her FSH levels?",
      "choices": [
        {
          "id": 1,
          "text": "On day 2-5 after last menstrual period"
        },
        {
          "id": 2,
          "text": "On day 11-14 after last menstrual period"
        },
        {
          "id": 3,
          "text": "On the day of menstruation"
        },
        {
          "id": 4,
          "text": "Just before menstruation"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<div class=\"page\" title=\"Page 79\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>The follicular stimulating hormone&nbsp;(<strong>FSH</strong>) level is studied on&nbsp;<strong>day</strong> <strong>2&ndash;5 after</strong>&nbsp;<strong>the</strong>&nbsp;<strong>last menstrual period</strong>&nbsp;to detect the <strong>premenopausal</strong> stage.</p>\n<p>It is a period of 3&ndash;4 years before menopause and is associated with mild ovarian hormonal deficiency leading to menstrual disorders, especially menorrhagia.</p>\n<p>The <strong>climacteric&nbsp;phase</strong> is the phase of waning of ovarian activity. It begins 2 to 3 years before menopause and may continue 2-5 years after menopause.&nbsp;It marks the <strong>transition from active to inactive ovarian function</strong> and involves physical, sexual, and psychological adjustments.</p>\n<p>The <strong>predictors </strong>of <strong>approaching menopause</strong> include:</p>\n<ul>\n<li>A <strong>fall</strong> in the level of <strong>inhibin B</strong> and a corresponding <strong>rise</strong> in <strong>FSH</strong> level</li>\n<li>A <strong>fall</strong> in the level of anti-Mullerian hormone (<strong>AMH</strong>) - This is a better marker of ovarian reserve and can be tested on any day of the cycle.</li>\n</ul>\n</div>\n</div>\n</div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC0879",
      "difficulty": "medium"
    },
    {
      "text": "What is the diagnostic value of FSH in menopause?",
      "choices": [
        {
          "id": 1,
          "text": "> 40 mIU/mL"
        },
        {
          "id": 2,
          "text": ">30 mIU/mL"
        },
        {
          "id": 3,
          "text": ">50 mIU/mL"
        },
        {
          "id": 4,
          "text": ">20 mIU/mL"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p>The diagnostic value of <strong>FSH</strong> in menopause is<strong> &gt;40 mIU/mL</strong>.</p>\n<p>Hormone levels in menopausal women:</p>\n<table>\n<tbody>\n<tr>\n<td><strong>Hormone</strong></td>\n<td><strong>Level</strong></td>\n</tr>\n<tr>\n<td>Estradiol </td>\n<td>5 to 25 pg/ml</td>\n</tr>\n<tr>\n<td>FSH</td>\n<td>&gt;40 mIU/mL</td>\n</tr>\n<tr>\n<td>LH</td>\n<td>50-100 mIUL/ml</td>\n</tr>\n<tr>\n<td>Growth hormone, inhibin B,<strong> </strong>AMH </td>\n<td>Decreases </td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC0893",
      "difficulty": "medium"
    },
    {
      "text": "What is the average age of menopause?",
      "choices": [
        {
          "id": 1,
          "text": "55 years"
        },
        {
          "id": 2,
          "text": "47 years"
        },
        {
          "id": 3,
          "text": "45 years"
        },
        {
          "id": 4,
          "text": "50 years"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>The average age of menopause in India is <strong>47 years,</strong>&nbsp;and ranges from 45&nbsp;to 50 years.&nbsp;</p>\n<p>Menopause sets in when the follicle number falls below 1000. If this happens <strong>before 40</strong> years, it is termed <strong>premature menopause</strong> while attaining it <strong>after 55</strong> years is <strong>delayed menopause</strong>.</p>\n<p>The age at which menopause is attained is not related to age at menarche, race, number of pregnancies, socio-economic status, or oral contraceptive pills usage. However, it is directly <strong>influenced</strong> by <strong>smoking</strong> and <strong>genetic</strong> disposition.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC0886",
      "difficulty": "medium"
    },
    {
      "text": "A menopausal woman presents with complaints of hot flushes. Which of the following neurotransmitters are responsible for these symptoms?",
      "choices": [
        {
          "id": 1,
          "text": "Serotonin and epinephrine"
        },
        {
          "id": 2,
          "text": "Serotonin and norepinephrine"
        },
        {
          "id": 3,
          "text": "Adrenaline and epinephrine"
        },
        {
          "id": 4,
          "text": "Noradrenaline and epinephrine"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p><strong>Norepinephrine</strong> and <strong>serotonin</strong> are responsible for hot flushes in menopausal women.</p>\n<p>A fall in the level of estrogen causes a reduction in hypothalamic endorphins. This causes a release of more norepinephrine and serotonin, which <strong>lower</strong> the <strong>set point</strong> in the&nbsp;<strong>thermoregulatory nucleus</strong>. As a result, the heat-loss mechanism is triggered by even subtle changes in core body temperature.</p>\n<p>Risk factors for hot flushes:</p>\n<ul>\n<li>Low estradiol levels</li>\n<li>High BMI</li>\n<li>Sedentary lifestyle</li>\n<li>Surgical menopause has increased risk</li>\n<li>Low socioeconomic status</li>\n<li>History of premenstrual dysphoric disorder (PMDD)</li>\n<li>Depression.</li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC0902",
      "difficulty": "medium"
    },
    {
      "text": "A 53-year-old woman presents with episodes of sensation of intense heat involving the face and upper chest which rapidly spreads across the entire body. The episodes last about 2-4 minutes and are associated with profuse sweating. What is the most effective treatment for her?",
      "choices": [
        {
          "id": 1,
          "text": "Combined Oral contraceptive pills"
        },
        {
          "id": 2,
          "text": "Clonidine"
        },
        {
          "id": 3,
          "text": "Estrogen therapy"
        },
        {
          "id": 4,
          "text": "Danazol"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>The clinical features are suggestive of vasomotor symptoms<strong> (hot flushes) </strong>in a menopausal woman for which the most effective treatment is<strong> estrogen therapy.</strong></p>\n<p>Treatment options include:</p>\n<ul>\n<li>Hormonal\n<ul>\n<li>Estrogen therapy - most effective</li>\n<li>Combined OC pills - given when estrogen is contraindicated</li>\n<li>Tibolone</li>\n</ul>\n</li>\n<li>Non-hormonal\n<ul>\n<li>Clonidine</li>\n<li>SSRIs (eg: fluoxetine)</li>\n<li>Dopamine antagonist</li>\n</ul>\n</li>\n<li>Non-prescriptive\n<ul>\n<li>Vitamin E</li>\n<li>Soya</li>\n<li>Isoflavones</li>\n</ul>\n</li>\n</ul>\n<p>Hormone therapy is only indicated for the treatment of vasomotor symptoms, osteoporosis (prevention and treatment), and vaginal atrophy. </p>\n<p>Endometrial hyperplasia can occur after 6 months of estrogen therapy. Hence, for patients with a uterus, it is recommended to <strong>add micronized progesterone</strong>. This is not necessary for women who have undergone hysterectomy.</p>\n<p>Note: Even though OCPs contain both estrogen and progesterone, a lesser dosage of each component is given for the treatment of hot flushes.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC0903",
      "difficulty": "medium"
    },
    {
      "text": "A 53-year-old postmenopausal lady presented with complaints of dyspareunia and vaginal spotting. On examination, the vagina appeared pale with small petechiae. Transvaginal ultrasound revealed a 3mm thick endometrium with no abnormality. Which among the following would be the next step in management?",
      "choices": [
        {
          "id": 1,
          "text": "Pipelle biopsy"
        },
        {
          "id": 2,
          "text": "Estradiol-releasing vaginal ring"
        },
        {
          "id": 3,
          "text": "Mirena intrauterine device"
        },
        {
          "id": 4,
          "text": "Hysteroscopy"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>The clinical scenario is suggestive of <strong>atrophic vaginitis.</strong> The next step in management should be<strong> </strong>topical estrogen therapy such as<strong> </strong>the<strong> estradiol-releasing vaginal ring</strong>.</p>\n<div class=\"ng-scope\">\n<div class=\"ng-scope\">\n<p>Atrophic vaginitis is a common cause of <strong>post-menopausal bleeding</strong> due to low estradiol levels. Patients may present with <strong>dry vagina</strong>, <strong>dyspareunia</strong> and a purulent or blood-tinged discharge. The vagina appears pale, dry, and may show petechiae.</p>\n<p>Treatment of atrophic vaginitis involves <strong>topical estrogens</strong> in the form of creams, tablets, or rings. Estrogen replacement restores vaginal mucosal elasticity, vaginal fluid secretion levels, blood flow, and sensorimotor responses.</p>\n<p><strong>Systemic</strong> therapy may help <strong>prevent recurrence</strong>. Vaginal lubricants and moisturizers can be given for symptomatic relief.</p>\n<p><strong>FOGSI guidelines</strong> for evaluation of postmenopausal bleeding:</p>\n</div>\n</div><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/55d581eb2bec4ed98c97379fefb1d716x1280x2320.JPEG\" alt=\"Explanation Image\">",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MF1574",
      "difficulty": "medium"
    },
    {
      "text": "Reduction in breast size in post-menopausal women is due to the withdrawal of ______.",
      "choices": [
        {
          "id": 1,
          "text": "Estrogen"
        },
        {
          "id": 2,
          "text": "Progesterone"
        },
        {
          "id": 3,
          "text": "Estrogen and progesterone"
        },
        {
          "id": 4,
          "text": "FSH"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>The<strong> reduction in breast size</strong>&nbsp;in postmenopausal women is due to the&nbsp;<strong>withdrawal of estrogen and progesterone</strong>.&nbsp;</p>\n<p><strong>Estrogen</strong> exerts proliferative effects on the <strong>ductal</strong> component, while <strong>progesterone</strong> exerts a proliferative effect on the <strong>glandular</strong> component.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC0907",
      "difficulty": "medium"
    },
    {
      "text": "A 67-year-old woman is being screened for osteoporosis with a DEXA scan. Which of the following sites are useful for the detection of early rapid bone loss?",
      "choices": [
        {
          "id": 1,
          "text": "Lumbar vertebra"
        },
        {
          "id": 2,
          "text": "Radius"
        },
        {
          "id": 3,
          "text": "Shaft of femur"
        },
        {
          "id": 4,
          "text": "Wrist"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p><strong>Early rapid bone loss</strong> can be determined from a dual-energy x-ray absorptiometry (<strong>DEXA</strong>) scan of the&nbsp;<strong>hip and lumbar vertebra</strong>.</p>\n<p>The risk for most fractures is inversely proportional to bone density. The <strong>reference standard</strong> for the diagnostic purpose is DEXA at the hip&nbsp;(<strong>femoral neck or total hip</strong>). These sites are superior to the spine in predicting hip as well as an overall osteoporotic fracture.</p>\n<div class=\"page\" title=\"Page 506\">\n<div class=\"section\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<div class=\"page\" title=\"Page 506\">\n<div class=\"section\">\n<div class=\"layoutArea\">\n<div class=\"column\">DEXA is used to assess bone mineral density (BMD). It is interpreted as follows:\n<table>\n<tbody>\n<tr>\n<td>Condition&nbsp;</td>\n<td>T Score range</td>\n</tr>\n<tr>\n<td>Normal</td>\n<td>+2.5 and -1.0</td>\n</tr>\n<tr>\n<td>Osteopenia</td>\n<td>-1.0 and -2.5</td>\n</tr>\n<tr>\n<td><strong>Osteoporosis</strong></td>\n<td><strong>-2.5 and below</strong></td>\n</tr>\n<tr>\n<td>Severe or established osteoporosis</td>\n<td>\n<p>-2.5 and below with one or more fractures&nbsp;</p>\n<p>OR</p>\n<p>-3.5 or below even in the absence of fractures</p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n</div>\n</div>\n</div>\n</div>\n</div>\n</div>\n</div>\n</div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC0905",
      "difficulty": "easy"
    },
    {
      "text": "Hormone replacement therapy is not indicated in which of the following patients?",
      "choices": [
        {
          "id": 1,
          "text": "45-year-old woman with severe hot flushes"
        },
        {
          "id": 2,
          "text": "36-year-old woman with premature menopause"
        },
        {
          "id": 3,
          "text": "An adolescent with gonadal dysgenesis"
        },
        {
          "id": 4,
          "text": "50-year-old woman with ischemic heart disease"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<div class=\"page\" title=\"Page 83\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>HRT is no longer recommended for the management of menopausal women with ischemic heart disease.</p>\n<p><strong>Indications</strong> for <strong>HRT</strong> is as follows:</p>\n<ul>\n<li>Severe hot flushes</li>\n<li>Premature menopause</li>\n<li>Surgical oophorectomy</li>\n<li>Turner syndrome (gonadal dysgenesis).</li>\n</ul>\n</div>\n</div>\n</div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC0913",
      "difficulty": "easy"
    },
    {
      "text": "Which of the following is not a contraindication for estrogen therapy?",
      "choices": [
        {
          "id": 1,
          "text": "Breast cancer"
        },
        {
          "id": 2,
          "text": "Uterine cancer"
        },
        {
          "id": 3,
          "text": "Previous history of thromboembolic episode"
        },
        {
          "id": 4,
          "text": "Hypertension"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<div class=\"page\" title=\"Page 84\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>Hypertension is not a contraindication for hormone replacement therapy (HRT). <strong>HRT</strong> can be initiated in patients with a history of <strong>hypertension, diabetes,</strong> or <strong>smoking</strong>; provided they are regularly <strong>monitored.</strong></p>\n<p><strong>Contraindications</strong> of estrogen therapy:</p>\n<div class=\"page\" title=\"Page 83\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<ul>\n<li>Breast cancer, uterine cancer, or family history of cancer</li>\n<li>Previous history of thromboembolic episode</li>\n<li>Liver and gall bladder diseases</li>\n<li>Uterine fibroids - as the fibroids may enlarge in size.</li>\n</ul>\n</div>\n</div>\n</div>\n</div>\n</div>\n</div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC0915",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following is incorrect about hormone replacement therapy and breast cancer?",
      "choices": [
        {
          "id": 1,
          "text": "Cancer risk is not increased up to 3 years of combined HRT"
        },
        {
          "id": 2,
          "text": "Cancer risk is not increased up to 5 years of estrogen-only replacement therapy"
        },
        {
          "id": 3,
          "text": "HRT impedes screening for breast cancer with mammography"
        },
        {
          "id": 4,
          "text": "HRT may cause high grade breast cancer with poor prognosis"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p>Breast cancer developing subsequent to HRT is of <strong>low grade</strong> and has a <strong>good prognosis</strong>.</p>\n<p>The risk of breast cancer is not increased up to 3 years of HRT and 5 years of estrogen-only replacement therapy. Lower risk is seen with the use of dydrogesterone in HRT.</p>\n<p><strong>HRT</strong> can cause <strong>recurrence</strong> of <strong>breast cancer</strong> and is, therefore, contraindicated in a woman who has been treated for breast cancer.</p>\n<p>HRT increases the density of breast tissue and subsequently <strong>impedes</strong> the <strong>screening</strong> for breast cancer with <strong>mammography</strong>.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC0918",
      "difficulty": "medium"
    },
    {
      "text": "You are prescribing estrogen therapy for a woman with hot flushes. What is the minimum number of days in a month during which you should combine it with progesterone?",
      "choices": [
        {
          "id": 1,
          "text": "8 days"
        },
        {
          "id": 2,
          "text": "10 days"
        },
        {
          "id": 3,
          "text": "12 days"
        },
        {
          "id": 4,
          "text": "14 days"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<div class=\"page\" title=\"Page 87\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>A minimum of <strong>12</strong> <strong>days</strong> (in a month) of progesterone must be added to estrogen therapy. This reduces the risk of endometrial cancer to 2%.&nbsp;</p>\n<p>The risk of cancer with estrogen therapy is dose and duration-dependent.&nbsp;<strong>Combined</strong> estrogen and progesterone provides better <strong>protection</strong> against <strong>endometrial cancer.&nbsp;</strong></p>\n<p>Tibolone is a safe drug and does not cause endometrial hyperplasia.&nbsp;</p>\n</div>\n</div>\n</div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC0920",
      "difficulty": "hard"
    },
    {
      "text": "A 50-year-old woman presents with complaints of vaginal bleeding and mentions that her last menstrual period was 10 months ago. What is the minimum duration of amenorrhoea following which she should be evaluated for possible causes? ",
      "choices": [
        {
          "id": 1,
          "text": "3 months"
        },
        {
          "id": 2,
          "text": "6 months"
        },
        {
          "id": 3,
          "text": "9 months"
        },
        {
          "id": 4,
          "text": "12 months"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p><strong>Vaginal bleeding</strong> occurring <strong>after 6 months</strong> of <strong>amenorrhoea</strong> in women of <strong>menopausal age group</strong> should be considered as <strong>postmenopausal bleeding</strong> and <strong>investigated</strong>. This must be done irrespective of a previous diagnosis of menopause.</p>\n<p>All postmenopausal women with unexpected uterine bleeding should be evaluated for <strong>endometrial carcinoma</strong>. Even in those women who are perimenopausal, endometrial carcinoma must be suspected if they fall under the above-mentioned clinical category.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC0921",
      "difficulty": "hard"
    },
    {
      "text": "What is the investigation of choice in a 55-year-old woman who presents with post-menopausal bleed?",
      "choices": [
        {
          "id": 1,
          "text": "Pap smear"
        },
        {
          "id": 2,
          "text": "Endometrial biopsy"
        },
        {
          "id": 3,
          "text": "Fractional curettage"
        },
        {
          "id": 4,
          "text": "CA-125 estimation"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p><strong>Endometrial biopsy&nbsp;</strong>is the investigation of choice in a case of <strong>post-menopausal bleed</strong>, as the chances of <strong>endometrial cancer</strong> are quite high.</p>\n<p>For those who undergo TVUS and have an <strong>EEC</strong> (endometrial echo complex) <strong>&gt;4 mm</strong>, localized thickening, or an <strong>indistinct</strong> or nonvisible EEC, <strong>endometrial sampling</strong> is a reasonable next step.</p>\n<p>Investigations for endometrial carcinoma include:</p>\n<ul>\n<li><strong>Endometrial aspiration biopsy </strong>is the&nbsp;first investigation in abnormal uterine bleeding, especially in females &gt;35 years.</li>\n<li>Dilatation and fractional curettage&nbsp;was the best method to diagnose but now it is not used.</li>\n<li><strong>Hysteroscopy and biopsy </strong>is the investigation of choice for endometrial cancer.</li>\n<li><strong>Transvaginal USG </strong>is used as an&nbsp;<strong>adjunct</strong> to endometrial biopsy.</li>\n<li>Pap smear is&nbsp;not reliable to diagnose endometrial carcinoma.&nbsp;It is more useful as a screening tool rather than a diagnostic tool.</li>\n</ul>\n<p>If symptoms of postmenopausal bleeding persist, imaging of the endometrial cavity should be performed with one or a combination of the following: TVUS, contrast sonography, or hysteroscopy.</p>\n<p>Note:&nbsp;<strong>Surgical staging</strong> is the gold standard investigation for staging endometrial carcinoma.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC0268",
      "difficulty": "medium"
    },
    {
      "text": "A 60-year-old woman presented with post-menopausal bleeding. Ultrasonography revealed a mass with feeding vessel as shown in the image below. What is the most likely diagnosis?",
      "choices": [
        {
          "id": 1,
          "text": "Fibroid uterus"
        },
        {
          "id": 2,
          "text": "Endometrial polyp"
        },
        {
          "id": 3,
          "text": "Endometrial carcinoma"
        },
        {
          "id": 4,
          "text": "Leiomyosarcoma"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p class=\"p1\">Visualization of a mass with a <strong>single</strong>&nbsp;<strong>feeding vessel</strong> on a color Doppler is characteristic of an&nbsp;<strong>endometrial polyp</strong>.&nbsp; In contrast, <strong>submucous leiomyomas</strong> often receive blood flow from <strong>multiple vessels</strong> (option A).&nbsp;</p>\n<p class=\"p1\"><strong>Endometrial polyps</strong> are <strong>soft, fleshy&nbsp;growths</strong> within the uterus that consist of endometrial glands, fibrous stroma, and surface epithelium.&nbsp;<strong>Risk factors</strong> for endometrial polyps include increasing age, obesity, and tamoxifen use.&nbsp;</p>\n<p class=\"p1\">They are usually asymptomatic. When symptomatic, they present with&nbsp;<strong>heavy menstrual bleeding</strong>, prolonged bleeding, <strong>intermenstrual bleeding</strong>, or infertility.&nbsp;</p>\n<p class=\"p1\">The main diagnostic tools for endometrial polyps include<strong> transvaginal ultrasound</strong> (TVS) with applied <strong>color Doppler</strong>, <strong>saline infusion sonography</strong>, and <strong>hysteroscopy</strong>.&nbsp;</p>\n<p class=\"p1\">The risk factors for the<strong> malignant transformation</strong> include <strong>postmenopausal status</strong>, <strong>age older than 60</strong>, and <strong>abnormal bleeding</strong>. Other factors such as larger polyp size (&gt;1.5 cm), tamoxifen use, diabetes, and obesity may also contribute to a higher risk.</p>\n<p class=\"p1\"><strong>Hysteroscopic polypectomy</strong> may be considered most effective for symptomatic women or those with risk factors for malignant transformation.&nbsp;</p>",
      "question_images": [
        "https://cdn1.dailyrounds.org/uploads/bc60247feaf5482a95ce6d4a7363401e.JPEG"
      ],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MD0829",
      "difficulty": "medium"
    },
    {
      "text": "A patient is planned to undergo hysteroscopic polypectomy using bipolar electrocautery. What is the ideal agent for distention?",
      "choices": [
        {
          "id": 1,
          "text": "Glycine"
        },
        {
          "id": 2,
          "text": "Normal saline"
        },
        {
          "id": 3,
          "text": "CO2"
        },
        {
          "id": 4,
          "text": "70% dextrose"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p><strong>Normal saline</strong> is the ideal fluid media used for <strong>bipolar</strong> electrocautery as it can function regardless of the fluid electrolyte content.&nbsp;</p>\n<p><strong>Normal saline and lactated Ringer solutions</strong> are commonly used <strong>isotonic, electrolyte-containing fluids</strong> in operating rooms for diagnostic hysteroscopy procedures.&nbsp;These solutions can cause <strong>volume overload</strong> and, if rapidly absorbed in large volumes, may lead to pulmonary edema.&nbsp;</p>\n<p>Isotonic, electrolyte-containing fluids&nbsp;are<strong> contraindicated</strong> for use with <strong>monopolar electrosurgical devices</strong> because they conduct electrical current, dissipate instrument energy and render the instrument ineffective.&nbsp;Low-viscosity, <strong>electrolyte-poor fluids</strong> such as <strong>1.5-percent glycine</strong>,<strong> 3-percent sorbitol</strong>, and<strong> 5-percent mannitol</strong> are preferred as they are non-conductive and can be safely used with monopolar electrosurgical energy devices.&nbsp;</p>\n<p>The primary risk of using hypotonic, hypoosmolar solutions is the <strong>intravascular</strong> absorption of these fluids, which can lead to <strong>acute hyponatremia</strong> and <strong>hypo osmolality</strong>.&nbsp;</p>\n<p>The criteria for <strong>terminating the procedure</strong> for <strong>electrolyte-deficient</strong> fluid is a deficit of <strong>1 L</strong> and <strong>electrolyte-rich</strong> fluid is a deficit of <strong>2.5 L</strong>.&nbsp;</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MD0824",
      "difficulty": "medium"
    }
  ]
}